Articles by Akbar K. Waljee, MD, MSc

Endoscopy Underuse for New-Onset Iron Deficiency Anemia in Younger Veterans
ByAndrew J. Read, MD, MS,Sarah L. Krein, PhD, RN,Kennedy DuBose, MPH,Tony Van, MS,Sameer D. Saini, MD, MS,Akbar K. Waljee, MD, MSc Bidirectional endoscopy (upper endoscopy and colonoscopy) was underutilized in the evaluation of new-onset iron deficiency anemia in younger veterans from 2005 to 2019.

Corticosteroid Premedication for Infliximab Remains Unnecessarily Common
ByShirley Cohen-Mekelburg, MD, MS,Jeffrey Gibbs, MD,Beth Wallace, MD, MS,Brooke Kenney, MPH,Akbar K. Waljee, MD, MSc Although use of corticosteroid premedication prior to infliximab infusions is declining, it remains unnecessarily high despite limited benefit and the risk of serious adverse events from corticosteroids.

Distinct Health Care Use Patterns of Patients With Chronic Gastrointestinal Diseases
ByShirley Cohen-Mekelburg, MD, MS,Liberty Greene, MS, MEd,Jeffrey Berinstein, MD, MS,Akbar K. Waljee, MD, MSc,Timothy P. Hofer, MD, MS,Sameer D. Saini, MD, MS,Donna M. Zulman, MD, MS Patients with complex chronic disease can be grouped by varying propensity for health care continuity patterns, which could be harnessed to personalize health care utilization interventions.

Inflammatory Bowel Disease Readmissions Are Associated With Utilization and Comorbidity
ByShirley Cohen-Mekelburg, MD, MS,Russell Rosenblatt, MD, MS,Beth Wallace, MD, MS,Nicole Shen, MD, MS,Brett Fortune, MD, MSc,Akbar K. Waljee, MD, MSc,Sameer Saini, MD, MS,Ellen Scherl, MD,Robert Burakoff, MD,Mark Unruh, PhD Thirty-day readmissions related to inflammatory bowel disease are common and associated with longer length of stay and a higher likelihood of having an associated comorbid condition compared with index hospitalizations.

Adalimumab Persistence for Inflammatory Bowel Disease in Veteran and Insured Cohorts
ByShail M. Govani, MD, MSc,Rachel Lipson, MSc,Mohamed Noureldin, MBBS, MSc,Wyndy Wiitala, PhD,Peter D.R. Higgins, MD, PhD, MSc,Sameer D. Saini, MD, MSc,Jacqueline A. Pugh, MD,Dawn I. Velligan, PhD,Ryan W. Stidham, MD, MSc,Akbar K. Waljee, MD, MSc Veterans with inflammatory bowel disease taking adalimumab appear to be more likely to remain on the drug 1 year after initiation than patients who are privately insured.